IL161833A0 - Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases - Google Patents

Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases

Info

Publication number
IL161833A0
IL161833A0 IL16183397A IL16183397A IL161833A0 IL 161833 A0 IL161833 A0 IL 161833A0 IL 16183397 A IL16183397 A IL 16183397A IL 16183397 A IL16183397 A IL 16183397A IL 161833 A0 IL161833 A0 IL 161833A0
Authority
IL
Israel
Prior art keywords
usethereof
thetreatment
pharmaceutical compositions
psychotic diseases
psychotic
Prior art date
Application number
IL16183397A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL161833A0 publication Critical patent/IL161833A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL16183397A 1996-09-23 1997-09-09 Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases IL161833A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2688496P 1996-09-23 1996-09-23
PCT/US1997/015874 WO1998011897A1 (en) 1996-09-23 1997-09-09 Combination therapy for treatment of psychoses

Publications (1)

Publication Number Publication Date
IL161833A0 true IL161833A0 (en) 2005-11-20

Family

ID=21834363

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16183397A IL161833A0 (en) 1996-09-23 1997-09-09 Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
IL12873097A IL128730A0 (en) 1996-09-23 1997-09-09 Combination therapy for treatment of psychoses

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12873097A IL128730A0 (en) 1996-09-23 1997-09-09 Combination therapy for treatment of psychoses

Country Status (30)

Country Link
US (1) US6147072A (cs)
EP (1) EP0830864B9 (cs)
JP (1) JP2001503031A (cs)
KR (1) KR100532901B1 (cs)
CN (1) CN1162156C (cs)
AR (1) AR008462A1 (cs)
AT (1) ATE231724T1 (cs)
AU (1) AU719033C (cs)
BR (1) BR9711530A (cs)
CA (1) CA2264941C (cs)
CO (1) CO4900058A1 (cs)
CZ (1) CZ301154B6 (cs)
DE (1) DE69718731T2 (cs)
DK (1) DK0830864T3 (cs)
EA (1) EA001317B1 (cs)
EG (1) EG24660A (cs)
ES (1) ES2191152T3 (cs)
HK (1) HK1009755A1 (cs)
HU (1) HU228178B1 (cs)
IL (2) IL161833A0 (cs)
MY (1) MY125564A (cs)
NO (1) NO319166B1 (cs)
NZ (1) NZ334168A (cs)
PE (1) PE110198A1 (cs)
PL (1) PL190374B1 (cs)
RS (1) RS49828B (cs)
TW (1) TW541178B (cs)
UA (1) UA62937C2 (cs)
WO (1) WO1998011897A1 (cs)
ZA (1) ZA977967B (cs)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
NZ508310A (en) * 1998-04-24 2005-03-24 Scarista Ltd Pharmaceutical composition containing folate precursor and a serotonin uptake inhibitor or a noradrenaline reuptake inhibitor useful for treating depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
KR20010043730A (ko) * 1998-05-22 2001-05-25 피터 지. 스트링거 치료 불응성 우울증의 치료를 위한 조합 치료법
WO1999062522A1 (en) * 1998-05-29 1999-12-09 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
WO2000024399A1 (en) * 1998-10-23 2000-05-04 Sepracor Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
JP2002530339A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． ２−ヒドロキシメチルオランザピン組成物及び方法
EP1027885B1 (en) * 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
JP4854115B2 (ja) 1999-03-12 2012-01-18 エイシカ ファーマシューティカルス リミテッド 無水パロキセチン用安定製剤形
AU4552200A (en) * 1999-05-12 2000-12-05 Solvay Pharmaceuticals B.V. Method of treating psychotic disorders
JP2003500353A (ja) * 1999-05-19 2003-01-07 アストラゼネカ・アクチエボラーグ 処置方法
AU4973800A (en) * 1999-06-09 2000-12-28 Eli Lilly And Company Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
CA2385749A1 (en) * 1999-09-28 2001-04-05 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AU3789901A (en) 1999-12-17 2001-06-25 Bristol-Myers Squibb Company Antipsychotic heterocycle compounds
EP1712222A3 (en) 1999-12-23 2012-06-20 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
CA2411386A1 (en) * 2000-06-30 2002-01-10 Eli Lilly And Company Combination therapy for treatment of psychoses
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) * 2000-12-05 2002-06-05 Phillip Branch Chappell Combination treatment for depression, anxiety and psychosis
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
JP2004518699A (ja) * 2001-02-06 2004-06-24 アストラゼネカ・アクチエボラーグ クエチアピンを用いた物質乱用の治療方法
US20020123490A1 (en) * 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US7034059B2 (en) 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
EP1575590B1 (en) 2002-12-27 2007-10-24 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05012325A (es) * 2003-05-16 2006-01-30 Pfizer Prod Inc Procedimiento para potenciar la cognicion usando zipirasidona.
WO2004100954A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
CA2525868A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Anxiety treatments with ziprasidone
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050032781A1 (en) * 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
EP1547650A1 (en) * 2003-12-02 2005-06-29 B & B Beheer NV Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1713486A4 (en) * 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY
CA2547639A1 (en) 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2007516292A (ja) * 2003-12-23 2007-06-21 ダーファーマ，インコーポレイテッド ドーパミン受容体結合化合物の共投与
WO2005070332A1 (en) * 2004-01-12 2005-08-04 The Trustees Of The University Of Pennsylvania Long-term delivery formulations and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
US20080269306A1 (en) * 2004-12-27 2008-10-30 Alpha 2 Pharmaceutica Ab Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) * 2005-09-08 2012-02-10 Х. Луннбэк А/С Стійкі тверді склади сертиндолу
US20070093471A1 (en) * 2005-10-26 2007-04-26 Alamo Pharmaceuticals, Llc Compositions and methods for the administration clozapine formulations which modulate body weight
WO2008095263A1 (en) * 2007-02-09 2008-08-14 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008122019A1 (en) * 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
RU2508096C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
RU2508106C2 (ru) * 2007-08-01 2014-02-27 Сергей Олегович Бачурин Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
NO2185155T3 (cs) * 2007-08-03 2018-03-03
CA2712282A1 (en) * 2008-01-25 2009-07-30 Alphapharm Pty Ltd Delayed release pharmaceutical composition of duloxetine
WO2011018801A2 (en) * 2009-08-12 2011-02-17 Genepharm India Pvt Ltd Solid oral dosage form of ziprasidone
US8865937B2 (en) 2009-11-06 2014-10-21 Mahendra G. Dedhiya Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015089494A1 (en) * 2013-12-13 2015-06-18 Ankenman Ralph Compositions and methods for treating dysregulated systems
KR102328058B1 (ko) * 2014-02-07 2021-11-17 뉴로크린 바이오사이언시즈 인코퍼레이티드 항정신병 약물 및 ｖｍａｔ２ 억제제를 포함하는 제약 조성물 및 그의 용도
PT3368534T (pt) 2015-10-30 2021-03-09 Neurocrine Biosciences Inc Ditosilato de valbenazina e polimorfos do mesmo
PT3394057T (pt) 2015-12-23 2022-04-21 Neurocrine Biosciences Inc Método sintético para a preparação de 2-amino-3-metilbutanoato de di(4-metilbenzenesulfonato) (s)-(2r,3r,11br)-3-isobutil-9,10-dimetoxi-2,3,4,6,7,11bhexaidro-1h-pirido[2,1,-a]lsoquinolin-2-ilo
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
SG11201906883SA (en) 2017-01-27 2019-08-27 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
CN116492340A (zh) 2017-10-10 2023-07-28 纽罗克里生物科学有限公司 施用某些vmat2抑制剂的方法
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
CN108938635A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种低剂量非典型抗精神病药物组合物
CN108938645A (zh) * 2018-08-24 2018-12-07 山西医科大学第医院 一种抗精神病药物组合物
CN108926569A (zh) * 2018-08-24 2018-12-04 山西医科大学第医院 一种非典型抗精神病药物组合物
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) * 2019-12-31 2022-06-24 北京鑫开元医药科技有限公司 一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5605897A (en) * 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
CA2250042A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
UA48219C2 (uk) * 1996-03-25 2002-08-15 Елі Ліллі Енд Компані Композиція для вгамування болю (варіанти) та спосіб вгамування болю
US5846928A (en) * 1996-08-01 1998-12-08 Pasken Products Co., Ltd. Method for treating cancer patients
US5877198A (en) * 1996-10-17 1999-03-02 Milkhaus Laboratory, Inc. Treatment of urinary incontinence

Also Published As

Publication number Publication date
PL332481A1 (en) 1999-09-13
EP0830864B9 (en) 2003-09-03
HUP9903905A2 (hu) 2000-10-28
DK0830864T3 (da) 2003-05-26
CN1230886A (zh) 1999-10-06
EA001317B1 (ru) 2001-02-26
JP2001503031A (ja) 2001-03-06
RS49828B (sr) 2008-08-07
CO4900058A1 (es) 2000-03-27
EP0830864A1 (en) 1998-03-25
PL190374B1 (pl) 2005-12-30
YU15299A (sh) 2002-06-19
MY125564A (en) 2006-08-30
US6147072A (en) 2000-11-14
BR9711530A (pt) 1999-08-24
CN1162156C (zh) 2004-08-18
ZA977967B (en) 1999-03-04
CA2264941A1 (en) 1998-03-26
CZ301154B6 (cs) 2009-11-18
PE110198A1 (es) 1999-01-21
CZ98799A3 (cs) 1999-12-15
HUP9903905A3 (en) 2001-03-28
UA62937C2 (uk) 2004-01-15
DE69718731D1 (de) 2003-03-06
AU719033B2 (en) 2000-05-04
NZ334168A (en) 2000-09-29
HU228178B1 (en) 2013-01-28
AR008462A1 (es) 2000-01-19
DE69718731T2 (de) 2003-09-11
KR20000048518A (ko) 2000-07-25
EA199900324A1 (ru) 1999-08-26
IL128730A0 (en) 2000-01-31
CA2264941C (en) 2008-11-18
NO319166B1 (no) 2005-06-27
WO1998011897A1 (en) 1998-03-26
NO991381L (no) 1999-03-22
HK1009755A1 (en) 1999-06-11
NO991381D0 (no) 1999-03-22
TW541178B (en) 2003-07-11
EG24660A (en) 2010-04-07
EP0830864B1 (en) 2003-01-29
KR100532901B1 (ko) 2005-12-02
AU4411297A (en) 1998-04-14
ATE231724T1 (de) 2003-02-15
ES2191152T3 (es) 2003-09-01
AU719033C (en) 2005-08-04

Similar Documents

Publication Publication Date Title
IL161833A0 (en) Pharmaceutical compositions and usethereof for thetreatment of psychotic diseases
EP0707446A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOM COMPLEXES
PL330814A1 (en) Compounds for and methods of delivering pharmaceutical preparations and their application
EG24044A (en) pharmaceutical formulation of omeprazole
HUP0103255A3 (en) Compositions and methods for treatment of mitochondrial diseases
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
ZA969001B (en) Method compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IL114877A0 (en) Derivatives of benzothiazepines pharmaceutical compositions containing them and their use
HUP9601698A3 (en) Pharmaceutical composition of adiabetical activity
GB9812056D0 (en) Pharmaceutical composition for treatment of ibd and rbd
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
AU2027595A (en) Pharmaceutical composition for treating inflammatory bowel diseases
GB2343117B (en) Benzimidazole pharmaceutical composition and process of preparation
AU5605398A (en) Novel methods and compositions for treatment of autoimmune diseases
EP0938901A4 (en) MEDICINAL COMPOSITIONS FOR TREATING HEPATIC CONDITIONS
IL114534A0 (en) Heterocyclic derivatives of azolones their preparaion and pharmaceutical compositions containing them
HUP9900147A2 (hu) Terápiás szerek és autoimmun betegségek kezelésére alkalmas gyógyszerkészítmények
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
AU2027495A (en) Pharmaceutical composition for treating hemorrhoidal diseases
HK1028561A1 (en) Pharmaceutical composition for reducing production of mcp-1 protein
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
AU5397496A (en) Low dose ridogrel formulations and their use for the treatme nt of inflammatory bowel diseases
EP0996441A4 (en) PHARMACEUTICAL COMPOSITIONS OF ARGLABIN AND ARGLABIN DERIVATIVES

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees